19.5
View the full transcript and gain access to JoVE Core videos
Q1: Why is epinephrine the first-line drug for all cardiac arrest rhythms?
Epinephrine is first-line because it increases coronary and cerebral perfusion through alpha-adrenergic vasoconstriction and enhances myocardial contractility via beta-1 receptor stimulation. These combined effects improve perfusion pressure and increase chances of successful resuscitation during cardiopulmonary resuscitation. Administer 1 mg intravenously or intraosseously every 3 to 5 minutes.
Q2: What is the difference between amiodarone and lidocaine for shock-refractory ventricular fibrillation?
Amiodarone blocks potassium, sodium, and calcium channels to stabilize the cardiac membrane, administered as 300 mg IV followed by 150 mg if needed. Lidocaine blocks sodium channels to suppress arrhythmias and is an alternative second-line option. Both are used after defibrillation and epinephrine fail to restore normal rhythm.
Q3: How do ACLS drug protocols differ between pulseless ventricular tachycardia and asystole?
For pulseless VT or VF, start with immediate defibrillation, then administer epinephrine every 3–5 minutes and antiarrhythmic drugs after the second shock. For asystole or pulseless electrical activity, administer epinephrine every 3–5 minutes while continuing high-quality CPR throughout resuscitation without defibrillation attempts.
Q4: What medications are used to manage hypotension after return of spontaneous circulation?
Norepinephrine is commonly used for post-ROSC hypotension due to potent vasoconstrictive effects, administered at 0.1–0.5 mcg/kg/min via central line. Dopamine may be considered for persistent hypotension with bradycardia, supporting both blood pressure and cardiac contractility at 5–10 mcg/kg/min. Both maintain hemodynamic stability during post-cardiac arrest care.
Q5: When is atropine indicated during post-cardiac arrest management?
Atropine is indicated for symptomatic bradycardia, particularly when associated with hypotension and poor perfusion. It increases heart rate by inhibiting parasympathetic influences. Administer 0.5 mg IV push, repeating every 3–5 minutes as needed, up to a total dose of 3 mg for chronotropic support.
Q6: How does targeted temperature management protect the brain after cardiac arrest?
Targeted Temperature Management reduces the risk of neurological injury by maintaining core body temperature between 32–36°C for at least 24 hours, followed by vigilant fever prevention. This neuroprotective strategy minimizes secondary neurological damage and is essential to post-cardiac arrest care protocols for improving survival outcomes.
Q7: What role does effective team communication play in ACLS outcomes?
Successful ACLS outcomes depend heavily on effective team dynamics with clearly assigned roles, consistent communication, and regular reassessment of interventions. All team members must be thoroughly familiar with resuscitation acls airway management protocols, including correct dosages, routes of administration, and timing of drug interventions to coordinate high-quality resuscitation efforts.